NCT04258826

A Study to Evaluate LY3154207 on the Brain of Healthy Participants

A Single-Dose Study Using Functional Magnetic Resonance Imaging to Evaluate the Effect of LY3154207 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3154207	LY3154207 administered orally.
DRUG	Placebo	Placebo administered orally.

Timeline

• Start date: 2021-01-15
• Primary completion: 2022-01-28
• Completion: 2022-01-28
• First posted: 2020-02-06
• Last updated: 2022-02-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study